Why the study?
The exon 18 D842V mutation in PDGFRA-mutant GISTs correlates with specific clinico-pathological features compared to other PDGFRA mutations, prompting evaluation of differences in miRNA expression profiles.
PDGFRA D842V mutant GISTs exhibit a distinct miRNA fingerprint compared to non-D842V mutated GISTs, potentially explaining their different biological behavior and implications for immunotherapy.
miRNA profiles differ in D842V vs non-D842V PDGFRA GISTs; hypothesis-generating for biomarker stratification in this rare subset.
Gastrointestinal stromal tumors (GISTs) harboring mutations in the PDGFRA gene occur in only about 5–7% of patients. The most common PDGFRA mutation is exon 18 D842V, which is correlated with specific clinico-pathological features compared to the other PDGFRA mutated GISTs. Herein, we present a miRNA expression profile comparison of PDGFRA D842V mutant GISTs and PDGFRA with mutations other than D842V (non-D842V). miRNA expression profiling was carried out on 10 patients using a TLDA miRNA array. Then, miRNA expression was followed by bioinformatic analysis aimed at evaluating differential expression, pathway enrichment, and miRNA-mRNA networks. We highlighted 24 differentially expressed miRNAs between D842V and non-D842V GIST patients. Pathway enrichment analysis showed that deregulated miRNAs targeted genes that are mainly involved in the immune response pathways. The miRNA-mRNA networks highlighted a signature of miRNAs/mRNA that could explain the indolent behavior of the D842V mutated GIST. The results highlighted a different miRNA fingerprint in PDGFRA D842V GISTs compared to non-D842Vmutated patients, which could explain the different biological behavior of this GIST subset.
No takes yet. Share an insight, caveat, or question.
Ravegnini et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: